Last reviewed · How we verify

NCT06644287

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas

Recruiting now Last updated 13 December 2024
What this trial tests

trial in Advanced Soft Tissue Sarcomas in 40 participants. Currently enrolling.

Timeline
15 October 2024
Primary endpoint
30 June 2026
31 July 2027

Quick facts

Lead sponsorRuijin Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment40
Start date15 October 2024
Primary completion30 June 2026
Estimated completion31 July 2027
Sites1 location across China

Conditions studied

Sponsor

Ruijin Hospital

Who can join

Adults 6 to 80, any sex, with Advanced Soft Tissue Sarcomas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced soft tissue sarcomas.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Ruijin Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06644287.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing